Request for Information: CPE CBRND Seeking Device Capable of Delivering Medical Countermeasure via Inhalation and Intramuscular Routes

The Joint Project Manager (JPM) for CBRN Medical, under the Capability Program Executive for Chemical, Biological, Radiological and Nuclear Defense (CPE CBRND), serves as the Department of War’s (DoW) premier program management office for the development and acquisition of safe, effective, and innovative medical solutions to combat Chemical, Biological, Radiological and Nuclear (CBRN) threats to service members.

JPM CBRN Medical leads medical countermeasure (MCM) development for vaccines, diagnostics, and therapeutics, which are critical elements to an integrated-layered defense strategy. The focus of this RFI is to survey current industry capabilities in the development, testing, and manufacturing of devices capable of delivering nalmefene via both inhalation (INH)/intranasal (IN) and intramuscular (IM) routes of administration for both prophylactic and therapeutic purposes.

This RFI aims to identify innovative solutions and assess the readiness of industry partners to address emerging operational needs effectively. This market research will also explore alternative methods to deliver both prophylactic and therapeutic MCMs in one device. Technologies must meet the following requirements: The device intended for IM and IN/INH delivery must be ruggedized and compliant with military (MIL) standards.

A single device must be designed to meet the requirements for eventual U.S. Food and Drug Administration (FDA) approval as both a therapeutic and prophylactic product and a medical device.

Responses to this RFI are requested no later than 12:00 PM ET Friday, 3 April 2026 Please respond to this RFI with the following details of your system's capability: White papers, concept briefs, and technical insights that detail the design feasibility, integration paths, operational readiness, and sustainment strategies for any solutions capable of meeting the above criteria. Summaries of studies performed to date would be beneficial. Submissions should be no more than five (5) pages. Past performances should be no more than one page. Ideal responses will include:

A technical description of the proposed approach (discussion of studies performed to date would be beneficial), a summary of relevant experience or past performance (no more than one (1) page), estimated timelines and scalability, identified sustainment considerations, potential cost drivers, and risk factors for development, FDA licensure, and fielding. Please visit the JETT page and select “Respond to an RFI” to share your capability with us. https://jacks.jpeocbrnd.army.mil/JETT